In the United Kingdom, a prominent epidemiologist reported that rare cases of blood clots (or blood clots) in people who have taken the Oxford / AstraZeneca vaccine against “Covid-19” can raise questions about whether they should Young people receive this vaccination version, amid reports that the Medicines Regulatory Authority in Britain is considering issuing new restrictions on the vaccine.
Professor Neil Ferguson, who personally received the Oxford vaccine, said that the risk of rare blood clots appears to be linked to age, as young people are more likely to be affected by blood clots compared to other age groups.
Following a review of the “Oxford-AstraZenica” vaccine by the British MHRA earlier this week, it said that there is currently no evidence indicating a causal relationship between blood clots and the “Oxford” immunization dose – and that the latter’s benefits are in protection. Coronavirus outweigh any other risks. It also indicated that 30 of the 18.1 million people who received the aforementioned vaccine in the United Kingdom had suffered blood clots, and that seven of them had died as a result, since March 24th.
However, the news program on “Channel 4” reported last Monday evening that the “Medicines and Healthcare Products Regulatory Authority” “is studying proposals to restrict giving young people the” Oxford-AstraZeneca “vaccine, adding that a decision may be taken in this regard soon.
This section contains Related Nodes field.
Speaking to “Today” on BBC Radio 4, Professor Ferguson said, “With regard to the current data, there is increasing evidence indicating that the” AstraZeneca “vaccine In particular, it poses a rare risk of these blood clots occurring, which do not usually appear when the number of platelets in the blood is low. However, other vaccines may also cause this condition, but at a lower level.
Professor Ferguson added, “The risk appears to be related to age, but data on it remain weak, and it may be related to gender as well.”
“Thus, the older you get, the lower the risk (the emergence of blood clots) and the increase at the same time the risk of infection with” Covid “, so in the equation of risks and benefits, the cuff tends to be strongly dependent on taking the vaccine,” according to Professor Ferguson.
“I think the issue gets a bit tougher when we get to the younger age groups, where the risk-benefit ratio is more complex,” he added.
Professor Ferguson said, “The Medicines and Healthcare Products Regulatory Authority” and the “Joint Committee for Vaccination and Immunization” (JCVI) in Britain are studying very urgently the potential risk of blood clots from the vaccine.
Dr June Raine, CEO of the Medicines and Healthcare Products Regulatory Authority, said, “People should not refrain from getting their vaccinations when they are asked to undergo vaccination.”
“We are continuing our comprehensive and detailed review regarding reports of very rare and specific types of blood clots associated with a decrease in platelets after taking the” AstraZeneca “vaccine, Dr. Rain said.
However, according to the CEO of the Medicines Regulatory Authority, “no decision has yet been taken regarding the issuance of any regulatory action” related to the vaccine.
Earlier this week, Dr. Raine stressed the “benefits of the AstraZeneca vaccine in preventing Covid-19 infection,” and said that the complications of the latter still outweigh any other risks, and people should proceed to get their vaccine when invited to do so. “.
As a reminder, concerns about the possible emergence of blood clots resulting from “Covid” vaccines have led some European countries to suspend offering the “Oxford” immunization version to their residents.
However, the European Medicines Agency (EMA) said that currently there is “no evidence” to support restricting the use of the vaccine in any population, indicating that the link to blood clotting is “not proven, but it is possible.”